Northrop Grumman Stock Falls 4.5% to $525.78

Shares post a fourth straight loss and their worst single-session decline since June.

Updated on Nov. 4, 2026 in Stock Picks

Northrop Grumman Stock Falls 4.5% to $525.78

Northrop Grumman stock fell 4.5% to $525.78 on November 4, 2026, extending a losing streak to four sessions. The defense contractor is also one of the 25 worst S&P 500 stocks to own in November over the last 10 years.

Why it matters

The decline pushes Northrop Grumman further below its March 3 record high of $774 and deepens its year-to-date loss to 7.7%. For U.S. investors holding the stock, the slide highlights how a historically weak November can weigh on a defense name even as analysts remain broadly optimistic.

Northrop Grumman's average November return is 0.6% with a 40% monthly win rate, and its 10-day call/put volume ratio stands at 3.04. Whether the stock recovers before month-end or analyst ratings shift has not yet been determined.

The players

Northrop Grumman

A major U.S. defense and aerospace contractor whose shares are tracked by S&P 500 investors.

L3Harris Technologies

A U.S. defense technology company that is the only other defense contractor on the list of 25 worst November stocks.

The details

Fifteen of 25 brokerages covering Northrop Grumman maintain strong buy ratings, while one maintains a sell rating. L3Harris Technologies is the only other defense contractor on the list of 25 worst November stocks.

March 3: Northrop Grumman set its record high of $774.
June: The stock recorded its previous worst single-session decline.
November 4, 2026: Shares fell 4.5% to $525.78.

Market Dynamics

Northrop Grumman's November slide fits a multiyear pattern in which the stock has ranked among the 25 weakest S&P 500 holdings for that month over the last decade. The pattern runs against the stock's broader analyst support, which still points to a $640.23 consensus target.

Investors holding Northrop Grumman have seen the stock slip from its March record high, and a $640.23 consensus target implies room to recover if analyst views hold. Individuals weighing a position should consider their own portfolio allocation and time horizon before acting on a single month's performance.

The takeaway

A single weak month does not determine a stock's long-term direction, but a pattern of poor November performance is worth weighing alongside analyst ratings and valuation before buying or selling.